Drug delivery

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 9, 2024
DAS, AMD, Boehringer Ingelheim, Research, Johnson & Johnson, Conference, Webcast, Conference call, Patient, M&A, CPT, Eye, Pharming, Conditional sentence, Data analysis, MBA, Drug delivery, Clinical trial, Biotechnology, ARVO, Visual acuity, Pharmaceutical industry

ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
  • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023.
  • Other expense for the first quarter of 2024 was $1.5 million, compared to $0 for the first quarter of 2023.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site

Retrieved on: 
星期一, 五月 6, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Medical Devices, Manufacturing, Clinical Trials, Other Health, European, HFA, Drug delivery, GWP, GMP, Kindeva, Isocyanate, Renewable energy

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
  • Kindeva’s first pMDI manufacturing line, which was announced in 2022 , is in its installation phase and will be completed later in 2024.
  • This second investment in low-GWP GMP manufacturing capacity further underscores Kindeva’s commitment to enable the pharmaceutical industry to meet its sustainability goals, whilst ensuring patient choice is not compromised.
  • Phase down of the existing propellants will commence in 2027 in the EU and be completed by the end of 2029.

Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations

Retrieved on: 
星期四, 四月 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Chemicals, Plastics, Manufacturing, Drug delivery, Administration, Johnson & Johnson, GWP, Kindeva, CDMO, Catalent, Patient, Multimedia, Teradyne, Biogen, Growth, Head, Pharmaceutical industry

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO).

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO).
  • Denis joins Kindeva to lead global operations for all Kindeva’s state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
  • Most recently, he served as Head of Global Manufacturing and Technical Operations at Biogen and held several leadership roles at Catalent, Boston Scientific, Teradyne, and Johnson & Johnson.
  • “I’m excited to join the Kindeva team to drive continued operational excellence and implement strategies that ensure the timely delivery of life-changing medications to patients worldwide.”

Global Drug Delivery Companies Compendium 2024: Intelligence on Drugs in the Development Pipeline from the Lab to the Market - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 18, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Intelligence, Drug delivery, Drug development, Compendium, Directory

The "Drug Delivery Companies Compendium 2024" directory has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery Companies Compendium 2024" directory has been added to ResearchAndMarkets.com's offering.
  • The Drug Delivery Companies Compendium is a cost-effective, time-saving product that answers all of your questions about Drug Delivery companies worldwide.
  • This Compendium contains in-depth reference source information on the top players in drug delivery, their major technology platforms, and their strategic alliances.
  • This informative database enables users to monitor the people, the products, and the financials behind today's global drug delivery market and will help you to:

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 三月 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services

Retrieved on: 
星期一, 三月 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Chemicals, Plastics, Manufacturing, CDMO, Conference, Business, Drug delivery, University, Curriculum, Multimedia

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit .

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit .
  • View the full release here: https://www.businesswire.com/news/home/20240318401921/en/
    Jennifer Riter joins Kindeva Drug Delivery as Vice President of Analytical Services to lead new analytical services business unit.
  • She brings specific leadership and expertise in analytical testing which includes extractables and leachables, container closure integrity and device/combination product performance, and particle analysis.
  • “Kindeva’s expertise in all areas of drug delivery and manufacturing is unmatched in the industry,” Riter said.

Kindeva Drug Delivery Launches New Analytical Services Global Business Unit

Retrieved on: 
星期三, 一月 31, 2024
Research, Medical Devices, Packaging, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, USP, Knowledge, CGMP, MD, Kindeva, ICH, Safety, CCI, Syringe, False vacuum decay, Drug delivery, Guideline, GMP, Fine chemical

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to the wider pharmaceutical, biopharmaceutical, and medical device sector.
  • For more than half a century, Kindeva has developed significant knowledge, experience, and expertise working on inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply.
  • Additionally, Kindeva has built deep expertise and capability in cGMP analytical services supporting its product development and supply partners.
  • In addition to increasing Kindeva’s global analytical footprint, Kindeva’s recently opened 32,000-square-foot state-of-the-art laboratories in Woodbury, Minnesota, will serve as the central hub for its expanded suite of stand-alone analytical services.

Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization

Retrieved on: 
星期四, 一月 18, 2024
Medical Devices, Medical Supplies, Chemicals, Plastics, Manufacturing, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, European Medicines Agency, CGMP, Drug delivery, EMA, Food, Acquisition, Laboratory, FDA, Workforce, CDMO, Kirkland & Ellis, Pharmaceutical industry

Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders.

Key Points: 
  • Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders.
  • Established in 2009, Summit has an extensive track record of innovation in the unit dose nasal spray market.
  • “Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting,” said Kindeva CEO Milton Boyer .
  • “Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale.

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 十一月 13, 2023
Potential, Visual acuity, Patient, Research, American Medical Association, Targeted drug delivery, Conference, American Academy of Ophthalmology, R, Diabetes, Diabetic retinopathy, Webcast, Literature, American Academy, Administration, DME, G&A, Research and development, Physician, Paratriathlon, Retina, Drug delivery, Pharming, Eye, Intravitreal injection, BioCryst Pharmaceuticals, SCS, Edema, AAO, Melanoma, AURA, Solubility, Partnership, AMD, Clearside, Bausch & Lomb, OASIS, Axitinib, Plasma, Clinical trial, CLS, CPT, Conference call, UME, Injection, HIV disease progression rates, Pharmaceutical industry, Nursing, Video game

ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
  • Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion

Retrieved on: 
星期二, 十二月 5, 2023
Other Manufacturing, Medical Devices, Medical Supplies, Chemicals, Plastics, Manufacturing, Other Health, Health, Pharmaceutical, General Health, Carbon, CDMO, Lung, DDL, Patient, Isocyanate, European, GWP, BMV, Pulmonary drug delivery, National Highway 152A (India), Partnership, Metered-dose inhaler, Drug delivery, Pharmaceutical industry, Engineered wood, Kindeva

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation , S.A.B.

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation , S.A.B.
  • de C.V. (BMV: ORBIA*) Fluorinated Solutions business ( Koura ®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.
  • View the full release here: https://www.businesswire.com/news/home/20231205198764/en/
    This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Koura’s Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice.
  • This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.